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Abstract
"Translational medicine" as a fashionable term is being increasingly used to describe the wish of
biomedical researchers to ultimately help patients. Despite increased efforts and investments into
R&D, the output of novel medicines has been declining dramatically over the past years.
Improvement of translation is thought to become a remedy as one of the reasons for this widening
gap between input and output is the difficult transition between preclinical ("basic") and clinical
stages in the R&D process. Animal experiments, test tube analyses and early human trials do simply
not reflect the patient situation well enough to reliably predict efficacy and safety of a novel
compound or device. This goal, however, can only be achieved if the translational processes are
scientifically backed up by robust methods some of which still need to be developed. This mainly
relates to biomarker development and predictivity assessment, biostatistical methods, smart and
accelerated early human study designs and decision algorithms among other features. It is therefore
claimed that a new science needs to be developed called 'translational science in medicine'.
Introduction
These days, "translational medicine" is a fashionable term
describing the inclination of biomedical researchers to
ultimately help patients.
As if this wish would be novel, it is being increasingly used
by scientific funding agencies (e.g. NIH, European Union
framework programs), regulatory authorities (e.g. FDA),
researchers and patient care providers.
This inflationary use has been triggered by a simple and
powerful fact: despite increased efforts and investments
into R&D, the output of novel medicines has been declin-
ing dramatically over the past years [1]. One of the reasons
for this widening gap between input and output is the dif-
ficult transition between preclinical ("basic") and clinical
stages in the R&D process. Animal experiments, test tube
analyses and early human trials do simply not reflect the
patient situation well enough to reliably predict efficacy
and safety of a novel compound or device.
Public and private responses in reflection of this observa-
tion have been numerous during the past years. This
includes the "Critical Path" initiative by the FDA [2], the
re-orientation of the NIH ("road-map"), enforced by Dr
Zerhouni's leadership towards translational medicine
with an estimated 10 billion USD channeled into transla-
tional medicine centers and other activities; major drug
companies and US universities (e.g. Duke or UPenn) are
being driven to establish translational medicine depart-
ments or at least working groups.
Measures and obstacles for translational 
medicine
So far, so good. But what has really happened and how do
we expect it to affect future R&D outcome?
Both in academia and industry, the wish to translate better
has increased the awareness for interface problems; in
academia, more clinical trials shall be performed as the
tougher variant of medical research if compared with test
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tube research. Clinical trials require a lot more resources,
paper work and endurance, and the rewards are still
smaller in the public appreciation (papers, impact fac-
tors). This challenge has been identified and a huge
amount of money is now supplied to investigator driven
trials in academia, especially through the translational
medicine centers by the NIH. The topic as such has been
reflected in numerous reviews and opinion papers, e.g. by
Sonntag [3] or Littman et al. [4] who in particular reflect
on the various hurdles opposing the progress of transla-
tional medicine such as scientific, financial, ethical, regu-
latory, legislative and practical problems. It should be
noted though that in Europe, investigator initiated trials
(IITs) as the most important manifestation of clinical
translational efforts in academia, are still rare and increas-
ingly burdened by legislatory (European drug laws, espe-
cially the 12th revision of the German 'Arzneimittelgesetz')
and financial constraints.
In industry, as both preclinical and clinical studies have
been performed routinely and professionally long before
this call for translational activities emerged, now the
major task is the intertwining and alignment of preclinical
and clinical studies along the artificially straight drug dis-
covery and development process. Here, it is more of an
interface problem, than reflecting the lack of access to
clinical trials. The main drawback of translational studies
and related personalized medicine approaches in industry
is the mandatory economical interest which is not in line
with all sophistications of drug profiling leading to nar-
rowed windows of opportunities. It seems that in some
instances, such translational efforts would have to come
from parallel, independent, presumably academic IITs.
In public science funding calls (e.g. EU Framework Pro-
gram 7) or scientific meetings (e.g. Endocrine Society
Meeting), "translational" seems to identify any proposal
or topic which involves clinical material and non-estab-
lished mechanistic approaches or early compound/medi-
cal device testing. Even epidemiology is coined as a
translational medicine tool, if patient data are analyzed.
Do those activities and interpretations of translational
medicine live up to the expectations raised by the original
motivation, namely to ultimately help patients?
The threat to increased output is the fact that most activities
under the umbrella "translational medicine" are preten-
tious and reflect phraseology, thus just wishful thinking.
Translational efforts are as old as medicine; all drugs on
the market had a successful translational process in their
history, and the wish to help patients by scientific tools
has been around for as long as medical science exists. If
the pressure exerted by lacking success just induces new
terminology for old processes, it is simply not enough to
warrant a major change. If success will not show, however,
biomedical science could even become a major loser in
the battle on investments into the future of mankind,
given e.g. the environmental and energy supply threats.
How to develop translational science in 
medicine?
What is lacking to ensure success, sustainability and sub-
stantial contributions of translational medicine?
As with all science, methods, systematic approaches and
tools are clues for success. This certainly applies to trans-
lational medicine. At present, the major weakness in its
fashionable surge is the lack of a scientific backbone. In
academia, translational programs to take new compounds
or devices systematically and under translational auspices
into man are almost completely lacking, and pathophysi-
ological studies of questionable relevance are rather being
induced by the new supply of money and increased pres-
sure to yield useful results. This is no true translation from
preclinical to clinical stages, thus, the translational aspect
is virtually lacking. In industry, better translation as a goal
is not supported by better tools or methods to improve
the translational process which had already been in place
(driven by necessity).
Those methods and tools to facilitate the translational proc-
ess need urgently to be developed. A major aspect in this
regard is the description and assessment of key indicators
in a translational process, so-called biomarkers, which are
needed for translational prediction. They are the main ele-
ments in predicting efficacy and safety from animal to man
and could be seen to be accountable for 80–90% of trans-
lational success. But they are very different. Some do not
even exist in humans (e.g. certain hormones), or cannot be
measured ethically (e.g. serial brain slices). This implies
that their values to predict translational outcomes are also
very different, and a scoring system for the predictive value
seems to represent a necessary tool in this process. The first
proposed quantitative biomarker scoring system depends
on 10 simple questions about e.g. accuracy, reproducibil-
ity, accessibility and human experience for a given biomar-
ker [5]. If applied to imaging biomarkers, this early system
seemed to produce reasonable scores if compared to "gut
feeling" scores which are the only ones available so far [6].
Those biomarkers, notabene, are the major tools in phar-
maceutical R&D to govern decisions worth 100–300 mil-
lion USD (e.g. investing in major phase III clinical trials).
It is obvious that the importance of biomarkers or other
tools of translational science do not only apply to pharma-
ceutical development, but are essential to translational
processes of medical devices or even procedural (e.g. surgi-
cal) developments.
This is just one example for an emerging tool in the nas-
cent science of translation. Many areas need developmentPublish with BioMed Central    and   every 
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alike including biostatistics (e.g. how to deal with multi-
ple read-out situations from expression analyses, gene
SNP analyses or serum markers panels), smart early clini-
cal trial design (this has been facilitated by microdosing
techniques and experimental IND [Investigational New
Drug] applications) and the discovery of novel biomark-
ers (not just grading of existing ones) fit for translational
purposes. Descriptive studies are relevant to translational
medicine in that they may point to essential hypothesis
and novel targets [7]. Human genetics provides powerful
tools for target validation to reflect back on preclinical
research, especially animal model development and its
routine application to target validation needs standardiza-
tion and refinement.
Imaging seems most promising in this regard as it is a
noninvasive and very informative tool which can be
applied across species including man, but this certainly is
not the answer to all needs. In terms of lacking biomark-
ers, safety biomarkers seem to be most antiquated (e.g.
liver transaminases which have been used for 50 years in
safety assessments), and certainly need fresh "injections"
most urgently.
The art of designing a translational medicine plan in drug
development can be hardly learned by a scientist who has
not gathered wide, concomitant preclinical and clinical
experiences. However, those scientists are still as rare as
natural diamonds; thus, education, breeding the transla-
tional scientist to be fit for purpose, would be a central
feature of this science as of any science.
Essential requirements for such plans should be defined
and a reproducible and widely applicable structure devel-
oped. The stop/go-decision reasoning in the development
process of drugs and non-drug innovations would gain
standardization, reproducibility and, thereby, increased
reliability. In this act, the assessment of biomarker validity
would represent an essential feature, and the construct of
smart clinical early trials would be build around those
capacities of developed and selected biomarker settings.
This list of tools (table 1) is by far not complete; it would
just name major elements which urgently need develop-
ment and could finally lead to something which would
deserve the term "translational science in medicine".
This science could be the most important novel medical
discipline in terms of patients' health to be developed in
the future. If successful, it should not only help individual
patients by novel diagnostic and treatment options, but
also prevent biomedicine from shrinking into oblivion
after decades of lack of success.
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Table 1: Tools of Translational Science in Medicine as backbone of an emerging science
New biomarker development, e.g. imaging or serum parameters
Translational toxicology including more powerful biomarkers
Biomarker scoring systems to grade their predictive potency
Smart, early human study design, including novel approaches e.g. microdosing and descriptive trials
Biostatistics development to cope with multiple read-out problems and small human studies
Human genetics